Prevention of Diabetes With Pioglitazone in ACT NOW
Open accessThe DOI matches its Crossref record, with a small difference in title or year; 42 of the 42 references it cites were found in a registry or an index.
Abstract
We examined the metabolic characteristics that attend the development of type 2 diabetes (T2DM) in 441 impaired glucose tolerance (IGT) subjects who participated in the ACT NOW Study and had complete end-of-study metabolic measurements. Subjects were randomized to receive pioglitazone (PGZ; 45 mg/day) or placebo and were observed for a median of 2.4 years. Indices of insulin sensitivity (Matsuda index [MI]), insulin secretion (IS)/insulin resistance (IR; ΔI0–120/ΔG0–120, ΔIS rate [ISR]0–120/ΔG0–120), and β-cell function (ΔI/ΔG × MI and ΔISR/ΔG × MI) were calculated from plasma glucose, insulin, and C-peptide concentrations during oral glucose tolerance tests at baseline and study end. Diabetes developed in 45 placebo-treated vs. 15 PGZ-treated subjects (odds ratio [OR] 0.28 [95% CI 0.15–0.49]; P < 0.0001); 48% of PGZ-treated subjects reverted to normal glucose tolerance (NGT) versus 28% of placebo-treated subjects (P < 0.005). Higher final glucose tolerance status (NGT > IGT > T2DM) was associated with improvements in insulin sensitivity (OR 0.61 [95% CI 0.54–0.80]), IS (OR 0.61 [95% CI 0.50–0.75]), and β-cell function (ln IS/IR index and ln ISR/IR index) (OR 0.26 [95% CI 0.19–0.37]; all P < 0.0001). Of the factors measured, improved β-cell function was most closely associated with final glucose tolerance status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, changes such as regression to IGT, maintenance of NGT, or progression to diabetes were proportional to insulin secretion response ( 67 ).”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [67]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 1×
“from PG and insulin levels obtained during the OGTT (23).”
BackgroundSelf-citationPrevalence of Obesity and Trends in the Distribution of Body Mass Index Among US Adults, 1999-2010
Flegal, K. M., Carroll, M. D., Kit, B. K., & Ogden, C. L. (2012) · JAMA · doi:10.1001/jama.2012.39 · Cited by 5,385 · cited 1×
“The prevalence of type 2 diabetes mellitus (T2DM) has risen to epidemic proportions in the United States and worldwide (1), and is being driven by the epidemic of obesity (2).”
BackgroundDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129 · cited 1×
“In contrast, PGZ does not increase the number of cardiovascular events (31,32).”
BackgroundThe Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456 · cited 2×
“Glucotoxicity has been implicated in progressive b-cell failure as individuals move from NGT to IGT to T2DM (8).”
BackgroundSelf-citationWeyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940 · cited 2×
“Alternatively, since PPAR-g is present in muscle/liver and b-cells (10,13), simultaneous PPAR-g activation in these tissues could explain the strong association between improved insulin sensitivity and enhanced b-cell function.”
BackgroundResultYki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · cited 2×
“PGZ reduces plasma free fatty acid (FFA) levels, mobilizes fat out of muscle (21) and liver (22), and redistributes fat from visceral to subcutaneous depots (12,16).”
BackgroundSelf-citationPPAR-gamma: adipogenic regulator and thiazolidinedione receptor.
Spiegelman, B. M. (1998) · Diabetes · doi:10.2337/diabetes.47.4.507 · Cited by 1,730
Buchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Self-citation
Cited by
Items 101–109 of 109
Thaipitakwong, T. (2020) · Chula Digiverse · doi:10.58837/chula.the.2020.367 · Cited by 3
Sadeghi, A., Asl, A. S., Babazadeh, D., & Simab, P. A. (2022) · Journal of Veterinary Physiology and Pathology · doi:10.58803/jvpp.v1i1.2
Predictors of Glycemic Worsening in the Next Year in Adults With Screen-Detected Type 2 Diabetes
Aguirre, R. S., Hannon, T. S., Considine, R. V., Patel, Y. R., Kirkman, M. S., & Mather, K. J. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doc25-0083
Effects of Lifestyle Modifications on Prediabetic Patients: A Quasi-Experimental Trial
Kumar, D., Hussain, S., Vazhappilly, B. J., Akbar, S., & Marius, A. F. (2025) · Cureus · doi:10.7759/cureus.78062 · Cited by 3
Hussain, I., MacLeod, J., Dunn, F., Bickel, P. E., Abreu, M., McNulty, N., Lingvay, I., Kermani, A., & Abreu, M. (2020) · American Diabetes Association eBooks · doi:10.2337/9781580406314.ch03
Gfi1 : a new target for diabetes therapy
Napolitano, T. (2017) · theses.fr (ABES) · doi:10.70675/aaf52a4az6ce1z446czae57z0d918d5706d5
Demidov, N. A. D., Demidova, T. Y., & Antsiferov, M. B. (2026) · FOCUS Endocrinology · doi:10.62751/2713-0177-2026-7-2-03
Marchant, E. D., Kalenta, H., Kilroe, S. P., May, J. T., Martini, W. Z., Weldon, K. S., Lai, Z., & Rasmussen, B. B. (2026) · Function · doi:10.1152/function.039.2026 · Cited by 1
“Furthermore, results from multiple randomized clinical trials, including in older individuals, suggest that pioglitazone, one of the only known insulin-sensitizing drugs, reduces the occurrence of diabetes in patients with insulin resistance and prediabetes (4 – 6).”
Kahn, S. E. (2026) · Diabetes · doi:10.2337/dbi25-0024 · Cited by 1
Metadata
- Authors
- DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Gastaldelli, A., Henry, R. R., Kitabchi, A. E., Mudaliar, S., Ratner, R. E., Stentz, F. B., Musi, N., Reaven, P. D., & Study, F. T. A. N.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Phoenix VA Health Care System (US)
- SUNY Downstate Health Sciences University (US)
- Pennington Biomedical Research Center (US)
- University of Southern California (US)
- Georgetown University (US)
- University of California San Diego (US)
- University of Tennessee Health Science Center (US)
- MedStar Health Research Institute (US)
- Corresponding author
- DeFronzo, Ralph A.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2013-10-18
- Volume
- 62
- Issue
- 11
- Pages
- 3920-3926
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3806596
- OpenAlex
- W2103930636
- Cited by
- 109
- References
- 42
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 5 · 2023: 5 · 2022: 7 · 2021: 12 · 2020: 11 · 2019: 6 · 2018: 8 · 2017: 8 · 2016: 11 · 2015: 7 · 2014: 14 · 2013: 2
- FWCI
- 8.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Gilead Sciences
- University of Southern California
- Intarcia Therapeutics
- Novo Nordisk
- National Institutes of Health (UL1TR000130)
- Health Science Center, University of Tennessee
- Allergan
- National Center for Research Resources (M01-RR00221)
- National Center for Advancing Translational Sciences
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- pioglitazone, type 2 diabetes prevention, impaired glucose tolerance, insulin sensitivity, Matsuda index, insulin secretion, insulin resistance, beta-cell function, glucose tolerance, thiazolidinediones
- MeSH terms
- Pioglitazone, Blood Glucose, Diabetes Mellitus, Type 2, Female, Glucose Tolerance Test, Humans, Insulin, Insulin Resistance, Male, Middle Aged, Glucose Intolerance, Thiazolidinediones, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.